SCHEDULE: Oxford Science Enterprises Discloses 7.2% Stake in PepGen
Ownership Disclosure
Oxford Science Enterprises plc has reported a 7.2% passive ownership stake in PepGen Inc., holding 4,955,388 shares of common stock.
Summary
- Oxford Science Enterprises plc has disclosed a beneficial ownership of 4,955,388 shares of PepGen Inc. common stock.
- This represents 7.2% of PepGen Inc.'s total outstanding common stock.
- The calculation is based on 68,737,224 shares outstanding as of September 26, 2025, as disclosed by PepGen Inc. in a prospectus supplement dated September 24, 2025.
- The filing indicates a passive investment, with Oxford Science Enterprises plc certifying that the shares were not acquired for the purpose of changing or influencing control of PepGen Inc.
Sentiment
Score: 7
Explanation: The disclosure of a significant, passive stake by a reputable institutional investor like Oxford Science Enterprises plc is generally viewed positively, indicating confidence in the company's value and prospects without implying activist intentions.
Positives
- A significant institutional investor, Oxford Science Enterprises plc, has taken a 7.2% stake in PepGen Inc., potentially signaling confidence in the company's long-term prospects.
- The passive nature of the investment, as certified by the reporting person, suggests a belief in current management and strategy.
Negatives
- No direct negatives are apparent from this passive ownership disclosure.
Risks
- The filing itself does not detail risks specific to PepGen Inc.'s operations or financial health.
- Oxford Science Enterprises plc has certified that its acquisition of shares is not for the purpose of changing or influencing control, mitigating immediate governance risks from this specific shareholder.
Future Outlook
NA
Industry Context
Oxford Science Enterprises plc is an investment company focused on commercializing scientific discoveries from the University of Oxford. Their significant stake in PepGen Inc. suggests a strategic interest in PepGen's specific therapeutic area or platform, aligning with their mission to support innovative science-based companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Shareholder Structure | Oxford Science Enterprises plc has become a significant shareholder, holding 7.2% of common stock. | 2025-09-30 | This establishes a notable institutional shareholder with a passive investment approach, as certified in the filing, indicating no immediate intent to influence control. |
Stakeholder Impact
- Shareholders: The presence of a significant institutional investor like Oxford Science Enterprises plc may be perceived as a vote of confidence, potentially stabilizing or positively influencing investor sentiment.
- Management: The passive nature of the investment suggests Oxford Science Enterprises plc is currently supportive of PepGen Inc.'s existing management and strategic direction.
Key Dates
| Date | Description |
|---|---|
| 2025-09-24 | Date of prospectus supplement filed by PepGen Inc. disclosing total shares outstanding. |
| 2025-09-25 | Date PepGen Inc. filed its prospectus supplement with the SEC. |
| 2025-09-26 | Date for which PepGen Inc.'s total shares outstanding (68,737,224) were reported. |
| 2025-09-30 | Date of event which required the filing of this statement (Oxford Science Enterprises plc crossed the 5% ownership threshold). |
| 2025-10-01 | Date the Schedule 13G Amendment No. 1 was signed and filed by Oxford Science Enterprises plc. |
Recommendation
holdThe filing indicates a significant, passive investment by Oxford Science Enterprises plc, which is generally a positive signal of institutional confidence. However, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data for PepGen Inc. to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future company performance and additional disclosures for more comprehensive insights.
Keywords
PepGen Inc., Oxford Science Enterprises plc, Common Stock, Ownership Disclosure, SEC Filing, Schedule 13G, Institutional Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.